Substrate
science

Research Reveals Long Dormancy Period for Active Volcano Methana in Greece

New research has found that the active volcano Methana near Athens, Greece, experienced a dormancy period of nearly 110,000 years. This discovery challenges traditional distinctions between volcanic dormancy and extinction. The findings were reported by @ScienceMagazine.

SC
1 source·Apr 24, 6:00 PM(11 days ago)·1m read
Research Reveals Long Dormancy Period for Active Volcano Methana in GreeceSubstrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

New research indicates that Methana, an active volcano located near Athens, Greece, remained dormant for nearly 110,000 years before resuming activity. This period of inactivity exceeds previous expectations for dormant volcanoes and raises questions about how to classify volcanoes as dormant or extinct.

The research highlights that such extended dormancy periods can occur in volcanoes still capable of eruption, altering prior scientific models.

The findings suggest a need to revisit criteria used to determine if a volcano is extinct, as long dormancy does not necessarily indicate permanent inactivity. Scientists may adjust monitoring protocols for similar volcanoes worldwide based on this evidence. @ScienceMagazine reported these details from the study, noting the complication to classic understandings of volcanic behavior.

Key Facts

Methana volcano
located near Athens, Greece
110,000 years
duration of past dormancy
Active status
despite long inactivity period
Scientific implication
challenges dormancy vs. extinction definitions

Story Timeline

2 events
  1. Recent

    Research published finding Methana volcano's 110,000-year dormancy period.

    1 source@ScienceMagazine
  2. Nearly 110,000 years ago

    Methana volcano ended a long dormancy and became active again.

    1 source@ScienceMagazine

Potential Impact

  1. 01

    Volcanologists may revise classification standards for dormant volcanoes globally.

  2. 02

    Further studies on Aegean volcanoes could follow this research.

  3. 03

    Increased monitoring could be implemented for volcanoes with long inactive periods.

  4. 04

    Public safety assessments near similar volcanoes might be updated.

Transparency Panel

Sources cross-referenced1
Framing risk0/100 (low)
Confidence score70%
Synthesized bySubstrate AI
Word count128 words
PublishedApr 24, 2026, 6:00 PM
Bias signals removed1 across 1 outlet
Signal Breakdown
Amplifying 1

Related Stories

Hantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Riskdeccanchronicle.com
science8 hrs agoDeveloping

Hantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Risk

A hantavirus outbreak on the MV Hondius cruise ship has killed three passengers and sickened seven others, prompting an international response coordinated by the World Health Organization. The ship, carrying 147 people from 23 nationalities, is set to sail to Spain's Canary Islan…

Stat
Cbs News
2 sources
Imperial College London Study Analyzes Changes in Wildfire Weather Patterns in Northern Irelandtechjuice.pk
science2 hrs agoDeveloping

Imperial College London Study Analyzes Changes in Wildfire Weather Patterns in Northern Ireland

A new report from Imperial College London highlights growing wildfire threats in Northern Ireland due to more favorable conditions, especially in spring. Researchers note increased drought and fire-prone weather, exacerbated by climate change. The findings point to longer fire se…

The Bbc
1 source
FDA Commissioner Defends Drug Rejection DecisionsThe U.S. Food and Drug Administration / Wikimedia (Public domain)
science14 hrs agoFraming55Framing risk55/100Lede misdirection foregrounds commissioner's defense over substantive drug rejections; inherited negative valence from sources on agency turmoil and backlash.Click to jump to full framing analysis

FDA Commissioner Defends Drug Rejection Decisions

The FDA commissioner defended recent drug rejections in a CNBC interview, citing adherence to scientific reviews amid reports of agency turmoil. Criticism includes a high-profile denial of a melanoma treatment from Replimune and pressure from President Trump over vape approvals.…

cnbc.com
Wall Street Journal
joemygod.com
3 sources